Dynavax Technologies Corp. (DVAX), which reported a 10% rise in revenue for its lead product in the first quarter, expects revenue to increase 24% to 31% for full year 2024.
The lead product is HEPLISAV-B, indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. CpG 1018 is the adjuvant used in HEPLISAV-B to provide an increased vaccine immune response.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.